How many months do you usually take Dramani/Delba? treatment cycle

Delamanid (Delamanid) is an anti-tuberculosis drug designed for patients with multidrug-resistant tuberculosis (MDR-TB). In clinical practice, the treatment cycle and medication regimen directly affect efficacy and tolerability, so patients and medical staff pay special attention to treatment time. According to international guidelines and overseas clinical experience, the standard use period of delamanid is usually 24 weeks, but the actual treatment needs to be extended with a combination regimen.

The recommended dose for adult patients is to take a certain dose of delamanid orally twice a day for 24 weeks. During this period, the drug should be managed through directly observed therapy (DOT) to ensure that the patient takes the drug on time and in sufficient amount to achieve optimal efficacy. DOT can not only improve patient compliance, but also detect and deal with adverse reactions in a timely manner during treatment.

After completing 24 weeks of delamanid treatment, patients usually need to continue receiving other anti-tuberculosis drug combinations to complete the entire MDR-TB treatment course. According to World Health Organization (WHO) guidelines, delamanid is mainly used in the initial stage of pathogen elimination, and combined with other drugs such as rifampicin and pyrazinamide to complete the full course of treatment, it can effectively reduce the risk of recurrence. The total treatment period varies depending on individual drug resistance type, disease severity and combination regimen, and generally ranges from 6 months to 18 months.

The dosing cycle for pediatric and adolescent patients is similar to that for adults, but the dose may be adjusted based on body weight or body surface area. Clinical data shows that after a standardized course of treatment, the sputum negative conversion rate of pediatric patients is close to that of adults, and the adverse reactions are controllable. This further demonstrates that delamanid has good applicability in the treatment of drug-resistant tuberculosis in different age groups.

It is worth noting that the efficacy of delamanid is closely related to continuous and sufficient dosage. Any early interruption, missed dose, or self-adjustment of dosage may lead to decreased efficacy, development of drug resistance, or even disease recurrence. Therefore, patients should strictly follow the doctor's instructions during use.

Reference: https://go.drugbank.com/drugs/DB11637